San Diego, CA -- (SBWIRE) -- 02/10/2016 -- An investigation for shareholders in GenVec Inc was announced concerning potential securities laws violations by GenVec.

Investors who purchased shares of GenVec Inc (NASDAQ:GNVC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by GenVec regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

GenVec Inc reported that its annual Total Revenue rose from $3.68 million in 2013 to $6.04 million in 2014 and that its Net Loss declined from $10.02 million in 2013 to $2.52 million in 2014. Shares of GenVec Inc (NASDAQ:GNVC) reached as high as $4.31 per share in early 2015.

On January 8, 2016, Novartis notified GenVec, a biopharmaceutical company, that it would be pausing enrollment for the CGF166 clinical trial to conduct a safety review of patient data, based on the recommendation of the trial's data safety monitoring board. The trial will continue to collect new safety and efficacy data on patients currently enrolled in the study. Shares of GenVec Inc (NASDAQ:GNVC) dropped to as low as $0.48 per share on February 8, 2016.

Those who purchased shares of GenVec Inc (NASDAQ:GNVC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com